| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | transcription coactivator activity | 1.02e-05 | 303 | 10 | 4 | GO:0003713 | |
| GeneOntologyMolecularFunction | acetylation-dependent protein binding | 1.04e-04 | 31 | 10 | 2 | GO:0140033 | |
| GeneOntologyMolecularFunction | transcription coregulator activity | 1.14e-04 | 562 | 10 | 4 | GO:0003712 | |
| GeneOntologyMolecularFunction | nuclear androgen receptor binding | 1.18e-04 | 33 | 10 | 2 | GO:0050681 | |
| GeneOntologyMolecularFunction | p53 binding | 6.47e-04 | 77 | 10 | 2 | GO:0002039 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 9.73e-04 | 417 | 10 | 3 | GO:0061629 | |
| GeneOntologyMolecularFunction | beta-catenin binding | 1.56e-03 | 120 | 10 | 2 | GO:0008013 | |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | 1.79e-03 | 1160 | 10 | 4 | GO:0030674 | |
| GeneOntologyMolecularFunction | transcription coregulator binding | 2.12e-03 | 140 | 10 | 2 | GO:0001221 | |
| GeneOntologyMolecularFunction | RNA polymerase II cis-regulatory region sequence-specific DNA binding | 2.32e-03 | 1244 | 10 | 4 | GO:0000978 | |
| GeneOntologyMolecularFunction | cis-regulatory region sequence-specific DNA binding | 2.52e-03 | 1271 | 10 | 4 | GO:0000987 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor binding | 2.54e-03 | 582 | 10 | 3 | GO:0140297 | |
| GeneOntologyMolecularFunction | chromatin DNA binding | 2.99e-03 | 167 | 10 | 2 | GO:0031490 | |
| GeneOntologyMolecularFunction | molecular adaptor activity | 3.19e-03 | 1356 | 10 | 4 | GO:0060090 | |
| GeneOntologyMolecularFunction | nuclear receptor binding | 3.74e-03 | 187 | 10 | 2 | GO:0016922 | |
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | 4.17e-03 | 1459 | 10 | 4 | GO:0000977 | |
| GeneOntologyMolecularFunction | modification-dependent protein binding | 4.51e-03 | 206 | 10 | 2 | GO:0140030 | |
| GeneOntologyMolecularFunction | chromatin binding | 4.98e-03 | 739 | 10 | 3 | GO:0003682 | |
| GeneOntologyMolecularFunction | transcription factor binding | 5.25e-03 | 753 | 10 | 3 | GO:0008134 | |
| GeneOntologyBiologicalProcess | regulation of sarcomere organization | 1.65e-05 | 13 | 10 | 2 | GO:0060297 | |
| GeneOntologyBiologicalProcess | positive regulation by host of viral transcription | 2.87e-05 | 17 | 10 | 2 | GO:0043923 | |
| GeneOntologyBiologicalProcess | myoblast differentiation | 3.25e-05 | 136 | 10 | 3 | GO:0045445 | |
| GeneOntologyBiologicalProcess | platelet formation | 6.83e-05 | 26 | 10 | 2 | GO:0030220 | |
| GeneOntologyBiologicalProcess | platelet morphogenesis | 7.94e-05 | 28 | 10 | 2 | GO:0036344 | |
| GeneOntologyBiologicalProcess | muscle cell differentiation | 8.06e-05 | 531 | 10 | 4 | GO:0042692 | |
| GeneOntologyBiologicalProcess | regulation of androgen receptor signaling pathway | 9.76e-05 | 31 | 10 | 2 | GO:0060765 | |
| GeneOntologyBiologicalProcess | skeletal muscle tissue development | 1.41e-04 | 223 | 10 | 3 | GO:0007519 | |
| GeneOntologyBiologicalProcess | skeletal muscle organ development | 1.76e-04 | 240 | 10 | 3 | GO:0060538 | |
| GeneOntologyBiologicalProcess | cell fate determination | 2.56e-04 | 50 | 10 | 2 | GO:0001709 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | 2.61e-04 | 1390 | 10 | 5 | GO:0045944 | |
| GeneOntologyBiologicalProcess | androgen receptor signaling pathway | 2.66e-04 | 51 | 10 | 2 | GO:0030521 | |
| GeneOntologyBiologicalProcess | positive regulation of cardiac muscle hypertrophy | 2.99e-04 | 54 | 10 | 2 | GO:0010613 | |
| GeneOntologyBiologicalProcess | positive regulation of myoblast differentiation | 2.99e-04 | 54 | 10 | 2 | GO:0045663 | |
| GeneOntologyBiologicalProcess | positive regulation of muscle hypertrophy | 3.10e-04 | 55 | 10 | 2 | GO:0014742 | |
| GeneOntologyBiologicalProcess | positive regulation of cardiac muscle tissue growth | 3.21e-04 | 56 | 10 | 2 | GO:0055023 | |
| GeneOntologyBiologicalProcess | viral transcription | 3.45e-04 | 58 | 10 | 2 | GO:0019083 | |
| GeneOntologyBiologicalProcess | behavioral defense response | 3.57e-04 | 59 | 10 | 2 | GO:0002209 | |
| GeneOntologyBiologicalProcess | sarcomere organization | 3.57e-04 | 59 | 10 | 2 | GO:0045214 | |
| GeneOntologyBiologicalProcess | positive regulation of heart growth | 3.69e-04 | 60 | 10 | 2 | GO:0060421 | |
| GeneOntologyBiologicalProcess | transcription initiation-coupled chromatin remodeling | 4.33e-04 | 65 | 10 | 2 | GO:0045815 | |
| GeneOntologyBiologicalProcess | cellular response to transforming growth factor beta stimulus | 4.72e-04 | 336 | 10 | 3 | GO:0071560 | |
| GeneOntologyBiologicalProcess | positive regulation of gene expression, epigenetic | 4.74e-04 | 68 | 10 | 2 | GO:0141137 | |
| GeneOntologyBiologicalProcess | positive regulation of striated muscle cell differentiation | 4.74e-04 | 68 | 10 | 2 | GO:0051155 | |
| GeneOntologyBiologicalProcess | cell fate commitment | 4.81e-04 | 338 | 10 | 3 | GO:0045165 | |
| GeneOntologyBiologicalProcess | response to transforming growth factor beta | 5.02e-04 | 343 | 10 | 3 | GO:0071559 | |
| GeneOntologyBiologicalProcess | megakaryocyte differentiation | 5.02e-04 | 70 | 10 | 2 | GO:0030219 | |
| GeneOntologyBiologicalProcess | muscle structure development | 5.11e-04 | 858 | 10 | 4 | GO:0061061 | |
| GeneOntologyBiologicalProcess | embryonic organ morphogenesis | 5.37e-04 | 351 | 10 | 3 | GO:0048562 | |
| GeneOntologyBiologicalProcess | positive regulation of organ growth | 5.46e-04 | 73 | 10 | 2 | GO:0046622 | |
| GeneOntologyBiologicalProcess | behavior | 5.89e-04 | 891 | 10 | 4 | GO:0007610 | |
| GeneOntologyBiologicalProcess | developmental growth | 6.41e-04 | 911 | 10 | 4 | GO:0048589 | |
| GeneOntologyBiologicalProcess | positive regulation of lymphocyte activation | 7.02e-04 | 385 | 10 | 3 | GO:0051251 | |
| GeneOntologyBiologicalProcess | striated muscle cell differentiation | 7.35e-04 | 391 | 10 | 3 | GO:0051146 | |
| GeneOntologyBiologicalProcess | myofibril assembly | 7.57e-04 | 86 | 10 | 2 | GO:0030239 | |
| GeneOntologyBiologicalProcess | regulation of intracellular steroid hormone receptor signaling pathway | 7.74e-04 | 87 | 10 | 2 | GO:0033143 | |
| GeneOntologyBiologicalProcess | striated muscle cell development | 8.10e-04 | 89 | 10 | 2 | GO:0055002 | |
| GeneOntologyBiologicalProcess | modulation by host of symbiont process | 8.47e-04 | 91 | 10 | 2 | GO:0051851 | |
| GeneOntologyBiologicalProcess | regulation of myoblast differentiation | 8.65e-04 | 92 | 10 | 2 | GO:0045661 | |
| GeneOntologyBiologicalProcess | intracellular receptor signaling pathway | 8.80e-04 | 416 | 10 | 3 | GO:0030522 | |
| GeneOntologyBiologicalProcess | outflow tract morphogenesis | 9.03e-04 | 94 | 10 | 2 | GO:0003151 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte activation | 9.23e-04 | 423 | 10 | 3 | GO:0002696 | |
| GeneOntologyBiologicalProcess | cognition | 9.23e-04 | 423 | 10 | 3 | GO:0050890 | |
| GeneOntologyBiologicalProcess | skeletal muscle cell differentiation | 9.42e-04 | 96 | 10 | 2 | GO:0035914 | |
| GeneOntologyBiologicalProcess | regulation of cardiac muscle hypertrophy | 9.61e-04 | 97 | 10 | 2 | GO:0010611 | |
| GeneOntologyBiologicalProcess | smooth muscle cell differentiation | 1.00e-03 | 99 | 10 | 2 | GO:0051145 | |
| GeneOntologyBiologicalProcess | muscle organ development | 1.01e-03 | 436 | 10 | 3 | GO:0007517 | |
| GeneOntologyBiologicalProcess | regulation of muscle hypertrophy | 1.02e-03 | 100 | 10 | 2 | GO:0014743 | |
| GeneOntologyBiologicalProcess | regulation of cardiac muscle tissue growth | 1.02e-03 | 100 | 10 | 2 | GO:0055021 | |
| GeneOntologyBiologicalProcess | regulation of miRNA metabolic process | 1.08e-03 | 103 | 10 | 2 | GO:2000628 | |
| GeneOntologyBiologicalProcess | regulation of DNA-binding transcription factor activity | 1.10e-03 | 449 | 10 | 3 | GO:0051090 | |
| GeneOntologyBiologicalProcess | positive regulation of cell activation | 1.10e-03 | 449 | 10 | 3 | GO:0050867 | |
| GeneOntologyBiologicalProcess | negative regulation of transcription by RNA polymerase II | 1.11e-03 | 1053 | 10 | 4 | GO:0000122 | |
| GeneOntologyBiologicalProcess | positive regulation of muscle cell differentiation | 1.15e-03 | 106 | 10 | 2 | GO:0051149 | |
| GeneOntologyBiologicalProcess | regulation of heart growth | 1.17e-03 | 107 | 10 | 2 | GO:0060420 | |
| GeneOntologyBiologicalProcess | viral gene expression | 1.21e-03 | 109 | 10 | 2 | GO:0019080 | |
| GeneOntologyBiologicalProcess | response to lipid | 1.42e-03 | 1126 | 10 | 4 | GO:0033993 | |
| GeneOntologyBiologicalProcess | miRNA metabolic process | 1.44e-03 | 119 | 10 | 2 | GO:0010586 | |
| GeneOntologyBiologicalProcess | regulation of actomyosin structure organization | 1.51e-03 | 122 | 10 | 2 | GO:0110020 | |
| GeneOntologyBiologicalProcess | regulation of striated muscle cell differentiation | 1.54e-03 | 123 | 10 | 2 | GO:0051153 | |
| GeneOntologyBiologicalProcess | regulation of muscle adaptation | 1.80e-03 | 133 | 10 | 2 | GO:0043502 | |
| GeneOntologyBiologicalProcess | biological process involved in interaction with symbiont | 1.85e-03 | 135 | 10 | 2 | GO:0051702 | |
| GeneOntologyBiologicalProcess | regulation of hemopoiesis | 1.87e-03 | 540 | 10 | 3 | GO:1903706 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated steroid hormone signaling pathway | 1.88e-03 | 136 | 10 | 2 | GO:0030518 | |
| GeneOntologyBiologicalProcess | cardiac muscle tissue growth | 1.93e-03 | 138 | 10 | 2 | GO:0055017 | |
| GeneOntologyBiologicalProcess | immune response-activating signaling pathway | 2.00e-03 | 553 | 10 | 3 | GO:0002757 | |
| GeneOntologyBiologicalProcess | growth | 2.01e-03 | 1235 | 10 | 4 | GO:0040007 | |
| GeneOntologyBiologicalProcess | cardiac muscle hypertrophy | 2.04e-03 | 142 | 10 | 2 | GO:0003300 | |
| GeneOntologyBiologicalProcess | positive regulation of immune system process | 2.05e-03 | 1242 | 10 | 4 | GO:0002684 | |
| GeneOntologyBiologicalProcess | myeloid cell differentiation | 2.05e-03 | 558 | 10 | 3 | GO:0030099 | |
| GeneOntologyBiologicalProcess | muscle tissue development | 2.05e-03 | 558 | 10 | 3 | GO:0060537 | |
| GeneOntologyBiologicalProcess | regulation of organ growth | 2.07e-03 | 143 | 10 | 2 | GO:0046620 | |
| GeneOntologyBiologicalProcess | embryonic organ development | 2.08e-03 | 561 | 10 | 3 | GO:0048568 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell differentiation | 2.10e-03 | 144 | 10 | 2 | GO:0045582 | |
| GeneOntologyBiologicalProcess | striated muscle hypertrophy | 2.16e-03 | 146 | 10 | 2 | GO:0014897 | |
| GeneOntologyBiologicalProcess | muscle hypertrophy | 2.22e-03 | 148 | 10 | 2 | GO:0014896 | |
| GeneOntologyCellularComponent | nuclear speck | 9.38e-04 | 431 | 10 | 3 | GO:0016607 | |
| GeneOntologyCellularComponent | sarcoplasm | 1.29e-03 | 114 | 10 | 2 | GO:0016528 | |
| GeneOntologyCellularComponent | chromatin | 3.72e-03 | 1480 | 10 | 4 | GO:0000785 | |
| GeneOntologyCellularComponent | nuclear body | 7.67e-03 | 903 | 10 | 3 | GO:0016604 | |
| HumanPheno | Hypoplasia of the phalanges of the toes | 5.07e-05 | 12 | 5 | 2 | HP:0010746 | |
| MousePheno | incomplete somite formation | 2.68e-04 | 44 | 8 | 2 | MP:0001689 | |
| MousePheno | ventricle myocardium hypoplasia | 6.98e-04 | 71 | 8 | 2 | MP:0010502 | |
| MousePheno | abnormal trabecula carnea morphology | 8.42e-04 | 78 | 8 | 2 | MP:0004067 | |
| MousePheno | myocardium hypoplasia | 1.02e-03 | 86 | 8 | 2 | MP:0010500 | |
| MousePheno | abnormal atrioventricular septum morphology | 1.05e-03 | 87 | 8 | 2 | MP:0010592 | |
| MousePheno | perimembraneous ventricular septal defect | 1.17e-03 | 92 | 8 | 2 | MP:0010418 | |
| MousePheno | abnormal interventricular septum membranous part morphology | 1.19e-03 | 93 | 8 | 2 | MP:0008823 | |
| MousePheno | ventricular hypoplasia | 1.35e-03 | 99 | 8 | 2 | MP:0000279 | |
| MousePheno | heart hypoplasia | 1.46e-03 | 103 | 8 | 2 | MP:0002740 | |
| MousePheno | impaired somite development | 1.49e-03 | 104 | 8 | 2 | MP:0009768 | |
| MousePheno | abnormal ventricle myocardium morphology | 1.85e-03 | 116 | 8 | 2 | MP:0010499 | |
| MousePheno | thin ventricular wall | 2.61e-03 | 138 | 8 | 2 | MP:0000280 | |
| MousePheno | abnormal vascular development | 2.81e-03 | 542 | 8 | 3 | MP:0000259 | |
| MousePheno | abnormal myocardial trabeculae morphology | 2.83e-03 | 144 | 8 | 2 | MP:0002189 | |
| MousePheno | hypoalgesia | 3.92e-03 | 170 | 8 | 2 | MP:0003043 | |
| Domain | Bromodomain_CS | 8.33e-05 | 26 | 10 | 2 | IPR018359 | |
| Domain | BROMODOMAIN_1 | 1.70e-04 | 37 | 10 | 2 | PS00633 | |
| Domain | Bromodomain | 1.80e-04 | 38 | 10 | 2 | PF00439 | |
| Domain | BROMODOMAIN_2 | 2.09e-04 | 41 | 10 | 2 | PS50014 | |
| Domain | BROMO | 2.20e-04 | 42 | 10 | 2 | SM00297 | |
| Domain | Bromodomain | 2.20e-04 | 42 | 10 | 2 | IPR001487 | |
| Domain | - | 2.20e-04 | 42 | 10 | 2 | 1.20.920.10 | |
| Pathway | REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX | 1.94e-07 | 26 | 7 | 3 | MM14793 | |
| Pathway | WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA | 3.23e-06 | 65 | 7 | 3 | M39682 | |
| Pathway | PID_RB_1PATHWAY | 3.23e-06 | 65 | 7 | 3 | M279 | |
| Pathway | PID_BETA_CATENIN_NUC_PATHWAY | 6.06e-06 | 80 | 7 | 3 | M223 | |
| Pathway | WP_DELTANOTCH_SIGNALING_PATHWAY | 6.53e-06 | 82 | 7 | 3 | MM15922 | |
| Pathway | REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX | 8.94e-06 | 91 | 7 | 3 | M27101 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 9.49e-06 | 10 | 7 | 2 | MM15535 | |
| Pathway | REACTOME_NOTCH2_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 1.39e-05 | 12 | 7 | 2 | M27159 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 1.92e-05 | 14 | 7 | 2 | M27808 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS | 2.53e-05 | 16 | 7 | 2 | M27121 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 3.22e-05 | 18 | 7 | 2 | MM14775 | |
| Pathway | REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 4.00e-05 | 20 | 7 | 2 | M27881 | |
| Pathway | WP_HEMATOPOIETIC_STEM_CELL_GENE_REGULATION_BY_GABP_ALPHABETA_COMPLEX | 4.42e-05 | 21 | 7 | 2 | M39593 | |
| Pathway | REACTOME_TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT | 4.68e-05 | 158 | 7 | 3 | MM14791 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 4.86e-05 | 22 | 7 | 2 | MM1370 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 5.80e-05 | 24 | 7 | 2 | M13404 | |
| Pathway | REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 6.31e-05 | 25 | 7 | 2 | M27880 | |
| Pathway | BIOCARTA_CARM_ER_PATHWAY | 6.83e-05 | 26 | 7 | 2 | M2499 | |
| Pathway | WP_PRION_DISEASE_PATHWAY | 1.04e-04 | 32 | 7 | 2 | M39636 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH2 | 1.11e-04 | 33 | 7 | 2 | M604 | |
| Pathway | REACTOME_RUNX1_INTERACTS_WITH_CO_FACTORS_WHOSE_PRECISE_EFFECT_ON_RUNX1_TARGETS_IS_NOT_KNOWN | 1.18e-04 | 34 | 7 | 2 | MM15531 | |
| Pathway | REACTOME_RUNX1_INTERACTS_WITH_CO_FACTORS_WHOSE_PRECISE_EFFECT_ON_RUNX1_TARGETS_IS_NOT_KNOWN | 1.40e-04 | 37 | 7 | 2 | M27797 | |
| Pathway | REACTOME_TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT | 1.49e-04 | 233 | 7 | 3 | M27099 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH | 1.55e-04 | 39 | 7 | 2 | MM14604 | |
| Pathway | REACTOME_SIGNALING_BY_WNT | 1.60e-04 | 239 | 7 | 3 | MM14756 | |
| Pathway | REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT | 1.80e-04 | 42 | 7 | 2 | M17541 | |
| Pathway | KEGG_NOTCH_SIGNALING_PATHWAY | 2.26e-04 | 47 | 7 | 2 | M7946 | |
| Pathway | WP_ENERGY_METABOLISM | 2.36e-04 | 48 | 7 | 2 | M39590 | |
| Pathway | WP_RETT_SYNDROME | 2.36e-04 | 48 | 7 | 2 | M39759 | |
| Pathway | REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 2.36e-04 | 48 | 7 | 2 | M611 | |
| Pathway | REACTOME_HEME_SIGNALING | 2.46e-04 | 49 | 7 | 2 | M41832 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH3 | 2.46e-04 | 49 | 7 | 2 | M618 | |
| Pathway | WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY | 3.17e-04 | 301 | 7 | 3 | MM15983 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER | 3.45e-04 | 58 | 7 | 2 | M29616 | |
| Pathway | WP_NOTCH_SIGNALING_WP61 | 3.81e-04 | 61 | 7 | 2 | M39540 | |
| Pathway | REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION | 3.81e-04 | 61 | 7 | 2 | M152 | |
| Pathway | REACTOME_SIGNALING_BY_WNT | 4.15e-04 | 330 | 7 | 3 | M7847 | |
| Pathway | REACTOME_FORMATION_OF_PARAXIAL_MESODERM | 4.88e-04 | 69 | 7 | 2 | M46439 | |
| Pathway | REACTOME_CIRCADIAN_CLOCK | 5.02e-04 | 70 | 7 | 2 | M938 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 5.61e-04 | 74 | 7 | 2 | M616 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3 | 5.92e-04 | 76 | 7 | 2 | MM15520 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH4 | 6.89e-04 | 82 | 7 | 2 | M594 | |
| Pathway | PID_REG_GR_PATHWAY | 6.89e-04 | 82 | 7 | 2 | M115 | |
| Pathway | PID_SMAD2_3NUCLEAR_PATHWAY | 6.89e-04 | 82 | 7 | 2 | M2 | |
| Pathway | WNT_SIGNALING | 8.11e-04 | 89 | 7 | 2 | M5493 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3 | 9.43e-04 | 96 | 7 | 2 | M27784 | |
| Pathway | REACTOME_DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS | 1.12e-03 | 464 | 7 | 3 | M27547 | |
| Pathway | WP_WNT_SIGNALING_PATHWAY | 1.24e-03 | 110 | 7 | 2 | MM15977 | |
| Pathway | REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING | 1.44e-03 | 119 | 7 | 2 | M607 | |
| Pathway | REACTOME_SIGNALING_BY_RECEPTOR_TYROSINE_KINASES | 1.67e-03 | 532 | 7 | 3 | M27870 | |
| Pathway | REACTOME_GASTRULATION | 1.69e-03 | 129 | 7 | 2 | M46433 | |
| Pathway | REACTOME_SIGNALING_BY_NTRKS | 1.83e-03 | 134 | 7 | 2 | M3574 | |
| Pathway | PID_P53_DOWNSTREAM_PATHWAY | 1.91e-03 | 137 | 7 | 2 | M145 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX1 | 2.37e-03 | 153 | 7 | 2 | MM15522 | |
| Pathway | WP_SUDDEN_INFANT_DEATH_SYNDROME_SIDS_SUSCEPTIBILITY_PATHWAYS | 2.56e-03 | 159 | 7 | 2 | M39373 | |
| Pathway | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION | 2.56e-03 | 1387 | 7 | 4 | M734 | |
| Pathway | REACTOME_DEVELOPMENTAL_BIOLOGY | 2.88e-03 | 1432 | 7 | 4 | M509 | |
| Pathway | REACTOME_GENERIC_TRANSCRIPTION_PATHWAY | 4.78e-03 | 768 | 7 | 3 | MM14851 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX1 | 5.59e-03 | 237 | 7 | 2 | M27786 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH | 6.01e-03 | 246 | 7 | 2 | M10189 | |
| Pathway | REACTOME_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION | 6.40e-03 | 254 | 7 | 2 | M27131 | |
| Pathway | REACTOME_CHROMATIN_MODIFYING_ENZYMES | 7.31e-03 | 272 | 7 | 2 | M29619 | |
| Pubmed | 7.44e-08 | 2 | 10 | 2 | 26459759 | ||
| Pubmed | 4.46e-07 | 4 | 10 | 2 | 30428346 | ||
| Pubmed | 4.46e-07 | 4 | 10 | 2 | 9001254 | ||
| Pubmed | Brahma safeguards canalization of cardiac mesoderm differentiation. | 4.46e-07 | 4 | 10 | 2 | 35082446 | |
| Pubmed | 7.44e-07 | 5 | 10 | 2 | 18487222 | ||
| Pubmed | 7.44e-07 | 5 | 10 | 2 | 28103279 | ||
| Pubmed | USP24 stabilizes bromodomain containing proteins to promote lung cancer malignancy. | 7.44e-07 | 5 | 10 | 2 | 33257797 | |
| Pubmed | 7.44e-07 | 5 | 10 | 2 | 19448667 | ||
| Pubmed | 8.67e-07 | 1429 | 10 | 6 | 35140242 | ||
| Pubmed | MyoD recruits the cdk9/cyclin T2 complex on myogenic-genes regulatory regions. | 1.12e-06 | 6 | 10 | 2 | 16245309 | |
| Pubmed | 1.55e-06 | 83 | 10 | 3 | 28794006 | ||
| Pubmed | Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. | 1.56e-06 | 7 | 10 | 2 | 9590696 | |
| Pubmed | Skeletal myosin light chain kinase regulates skeletal myogenesis by phosphorylation of MEF2C. | 1.56e-06 | 7 | 10 | 2 | 21556048 | |
| Pubmed | A switch from hBrm to Brg1 at IFNγ-activated sequences mediates the activation of human genes. | 1.56e-06 | 7 | 10 | 2 | 21079652 | |
| Pubmed | The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. | 1.56e-06 | 7 | 10 | 2 | 16687403 | |
| Pubmed | Interaction network of human early embryonic transcription factors. | 2.04e-06 | 351 | 10 | 4 | 38297188 | |
| Pubmed | 3.34e-06 | 10 | 10 | 2 | 35210568 | ||
| Pubmed | GCN5 and p300 share essential functions during early embryogenesis. | 3.34e-06 | 10 | 10 | 2 | 15937931 | |
| Pubmed | Targeting HIV transcription: the quest for a functional cure. | 4.09e-06 | 11 | 10 | 2 | 25731772 | |
| Pubmed | 4.09e-06 | 11 | 10 | 2 | 18003620 | ||
| Pubmed | Chromatin dynamics associated with HIV-1 Tat-activated transcription. | 4.90e-06 | 12 | 10 | 2 | 19716452 | |
| Pubmed | Skeletal muscle specification by myogenin and Mef2D via the SWI/SNF ATPase Brg1. | 4.90e-06 | 12 | 10 | 2 | 16424906 | |
| Pubmed | 4.90e-06 | 12 | 10 | 2 | 35132438 | ||
| Pubmed | 6.15e-06 | 131 | 10 | 3 | 34551306 | ||
| Pubmed | 7.80e-06 | 15 | 10 | 2 | 14701856 | ||
| Pubmed | 9.60e-06 | 152 | 10 | 3 | 38360978 | ||
| Pubmed | 1.01e-05 | 17 | 10 | 2 | 19183483 | ||
| Pubmed | 1.14e-05 | 18 | 10 | 2 | 33323119 | ||
| Pubmed | TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation. | 1.14e-05 | 18 | 10 | 2 | 28068325 | |
| Pubmed | 1.67e-05 | 183 | 10 | 3 | 36129980 | ||
| Pubmed | 2.05e-05 | 24 | 10 | 2 | 37543677 | ||
| Pubmed | Chromatin regulation by Brg1 underlies heart muscle development and disease. | 2.22e-05 | 25 | 10 | 2 | 20596014 | |
| Pubmed | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. | 3.01e-05 | 1489 | 10 | 5 | 28611215 | |
| Pubmed | 3.26e-05 | 709 | 10 | 4 | 22988430 | ||
| Pubmed | Placing the HIRA histone chaperone complex in the chromatin landscape. | 3.44e-05 | 31 | 10 | 2 | 23602572 | |
| Pubmed | 3.91e-05 | 33 | 10 | 2 | 32140074 | ||
| Pubmed | Gfi1b regulates the level of Wnt/β-catenin signaling in hematopoietic stem cells and megakaryocytes. | 4.15e-05 | 34 | 10 | 2 | 30894540 | |
| Pubmed | Pioneering function of Isl1 in the epigenetic control of cardiomyocyte cell fate. | 4.15e-05 | 34 | 10 | 2 | 31024170 | |
| Pubmed | 4.24e-05 | 250 | 10 | 3 | 18660489 | ||
| Pubmed | Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. | 5.20e-05 | 38 | 10 | 2 | 18267097 | |
| Pubmed | Identification and Functional Characterization of a Novel Androgen Receptor Coregulator, EAP1. | 5.77e-05 | 40 | 10 | 2 | 34585037 | |
| Pubmed | 1.07e-04 | 963 | 10 | 4 | 28671696 | ||
| Pubmed | 1.10e-04 | 55 | 10 | 2 | 35945219 | ||
| Pubmed | 1.53e-04 | 65 | 10 | 2 | 26655900 | ||
| Pubmed | 1.58e-04 | 66 | 10 | 2 | 23275444 | ||
| Pubmed | 1.78e-04 | 70 | 10 | 2 | 34255829 | ||
| Pubmed | 2.04e-04 | 75 | 10 | 2 | 25593309 | ||
| Pubmed | Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation. | 2.53e-04 | 457 | 10 | 3 | 32344865 | |
| Pubmed | 2.88e-04 | 89 | 10 | 2 | 18950845 | ||
| Interaction | MYOD1 interactions | 1.67e-06 | 194 | 10 | 4 | int:MYOD1 | |
| Interaction | MAML1 interactions | 5.37e-06 | 73 | 10 | 3 | int:MAML1 | |
| Interaction | MEF2A interactions | 6.07e-06 | 76 | 10 | 3 | int:MEF2A | |
| Interaction | SOX9 interactions | 1.27e-05 | 97 | 10 | 3 | int:SOX9 | |
| Interaction | NOTCH1 interactions | 1.63e-05 | 345 | 10 | 4 | int:NOTCH1 | |
| Interaction | SP1 interactions | 2.04e-05 | 365 | 10 | 4 | int:SP1 | |
| Interaction | TBXT interactions | 2.17e-05 | 116 | 10 | 3 | int:TBXT | |
| Interaction | SMAD2 interactions | 2.51e-05 | 385 | 10 | 4 | int:SMAD2 | |
| Interaction | KLF4 interactions | 5.66e-05 | 160 | 10 | 3 | int:KLF4 | |
| Interaction | TBX21 interactions | 6.08e-05 | 24 | 10 | 2 | int:TBX21 | |
| Interaction | EID2 interactions | 6.08e-05 | 24 | 10 | 2 | int:EID2 | |
| Interaction | GATA1 interactions | 6.89e-05 | 171 | 10 | 3 | int:GATA1 | |
| Interaction | EPAS1 interactions | 7.14e-05 | 173 | 10 | 3 | int:EPAS1 | |
| Interaction | HOXB7 interactions | 7.16e-05 | 26 | 10 | 2 | int:HOXB7 | |
| Interaction | MYOCD interactions | 8.93e-05 | 29 | 10 | 2 | int:MYOCD | |
| Interaction | GATA2 interactions | 1.08e-04 | 199 | 10 | 3 | int:GATA2 | |
| Interaction | NEUROD1 interactions | 1.09e-04 | 32 | 10 | 2 | int:NEUROD1 | |
| Interaction | NR1H4 interactions | 1.09e-04 | 32 | 10 | 2 | int:NR1H4 | |
| Interaction | KLF1 interactions | 1.46e-04 | 37 | 10 | 2 | int:KLF1 | |
| Interaction | ERG interactions | 1.51e-04 | 223 | 10 | 3 | int:ERG | |
| Interaction | FOXC1 interactions | 1.62e-04 | 228 | 10 | 3 | int:FOXC1 | |
| Interaction | IFRD1 interactions | 1.89e-04 | 42 | 10 | 2 | int:IFRD1 | |
| Interaction | EYA4 interactions | 1.95e-04 | 243 | 10 | 3 | int:EYA4 | |
| Interaction | ASCL1 interactions | 2.17e-04 | 45 | 10 | 2 | int:ASCL1 | |
| Interaction | RBPJ interactions | 2.22e-04 | 254 | 10 | 3 | int:RBPJ | |
| Interaction | MEF2C interactions | 3.13e-04 | 54 | 10 | 2 | int:MEF2C | |
| Interaction | CIITA interactions | 3.25e-04 | 55 | 10 | 2 | int:CIITA | |
| Interaction | SSBP4 interactions | 3.73e-04 | 59 | 10 | 2 | int:SSBP4 | |
| Interaction | SP7 interactions | 3.77e-04 | 304 | 10 | 3 | int:SP7 | |
| Interaction | HOXB6 interactions | 3.86e-04 | 60 | 10 | 2 | int:HOXB6 | |
| Interaction | MRTFA interactions | 3.86e-04 | 60 | 10 | 2 | int:MRTFA | |
| Interaction | ETS2 interactions | 3.99e-04 | 61 | 10 | 2 | int:ETS2 | |
| Interaction | FOS interactions | 4.07e-04 | 312 | 10 | 3 | int:FOS | |
| Interaction | PPP1R3A interactions | 4.53e-04 | 65 | 10 | 2 | int:PPP1R3A | |
| Interaction | CARM1 interactions | 4.58e-04 | 325 | 10 | 3 | int:CARM1 | |
| Interaction | ZYX interactions | 4.75e-04 | 329 | 10 | 3 | int:ZYX | |
| Interaction | SYNC interactions | 4.82e-04 | 67 | 10 | 2 | int:SYNC | |
| Interaction | GCM1 interactions | 4.96e-04 | 68 | 10 | 2 | int:GCM1 | |
| Interaction | ETV4 interactions | 5.11e-04 | 69 | 10 | 2 | int:ETV4 | |
| Interaction | EGR1 interactions | 5.56e-04 | 72 | 10 | 2 | int:EGR1 | |
| Interaction | MYOG interactions | 5.56e-04 | 72 | 10 | 2 | int:MYOG | |
| Interaction | MAPK14 interactions | 5.84e-04 | 353 | 10 | 3 | int:MAPK14 | |
| Interaction | SHOC2 interactions | 5.87e-04 | 74 | 10 | 2 | int:SHOC2 | |
| Interaction | BCL11B interactions | 5.87e-04 | 74 | 10 | 2 | int:BCL11B | |
| Interaction | SOX4 interactions | 6.19e-04 | 76 | 10 | 2 | int:SOX4 | |
| Interaction | UBN1 interactions | 6.36e-04 | 77 | 10 | 2 | int:UBN1 | |
| Interaction | PAX6 interactions | 6.48e-04 | 366 | 10 | 3 | int:PAX6 | |
| Interaction | HDAC9 interactions | 6.52e-04 | 78 | 10 | 2 | int:HDAC9 | |
| Interaction | MIER1 interactions | 6.86e-04 | 80 | 10 | 2 | int:MIER1 | |
| Interaction | HNF1A interactions | 6.86e-04 | 80 | 10 | 2 | int:HNF1A | |
| Interaction | TLE3 interactions | 7.01e-04 | 376 | 10 | 3 | int:TLE3 | |
| Interaction | STAT2 interactions | 7.03e-04 | 81 | 10 | 2 | int:STAT2 | |
| Interaction | NKX2-5 interactions | 7.21e-04 | 82 | 10 | 2 | int:NKX2-5 | |
| Interaction | SOX7 interactions | 7.21e-04 | 82 | 10 | 2 | int:SOX7 | |
| Interaction | SIN3A interactions | 7.23e-04 | 380 | 10 | 3 | int:SIN3A | |
| Interaction | IRF1 interactions | 7.38e-04 | 83 | 10 | 2 | int:IRF1 | |
| Interaction | USF1 interactions | 7.74e-04 | 85 | 10 | 2 | int:USF1 | |
| Interaction | CDX2 interactions | 7.92e-04 | 86 | 10 | 2 | int:CDX2 | |
| Interaction | MEF2D interactions | 8.11e-04 | 87 | 10 | 2 | int:MEF2D | |
| Interaction | STAT6 interactions | 8.11e-04 | 87 | 10 | 2 | int:STAT6 | |
| Interaction | GSC interactions | 8.11e-04 | 87 | 10 | 2 | int:GSC | |
| Interaction | CDK19 interactions | 8.29e-04 | 88 | 10 | 2 | int:CDK19 | |
| Interaction | SS18 interactions | 8.29e-04 | 88 | 10 | 2 | int:SS18 | |
| Interaction | NR3C1 interactions | 9.01e-04 | 974 | 10 | 4 | int:NR3C1 | |
| Interaction | FOXI1 interactions | 9.06e-04 | 92 | 10 | 2 | int:FOXI1 | |
| Interaction | SOX10 interactions | 9.06e-04 | 92 | 10 | 2 | int:SOX10 | |
| Interaction | GATA4 interactions | 9.08e-04 | 411 | 10 | 3 | int:GATA4 | |
| Interaction | PALS2 interactions | 9.25e-04 | 93 | 10 | 2 | int:PALS2 | |
| Interaction | DPF3 interactions | 9.65e-04 | 95 | 10 | 2 | int:DPF3 | |
| Interaction | WWTR1 interactions | 9.80e-04 | 422 | 10 | 3 | int:WWTR1 | |
| Interaction | NUP35 interactions | 9.94e-04 | 424 | 10 | 3 | int:NUP35 | |
| Interaction | SS18L1 interactions | 1.03e-03 | 98 | 10 | 2 | int:SS18L1 | |
| Interaction | CTNNB1 interactions | 1.03e-03 | 1009 | 10 | 4 | int:CTNNB1 | |
| Interaction | ING1 interactions | 1.13e-03 | 103 | 10 | 2 | int:ING1 | |
| Interaction | STAT3 interactions | 1.15e-03 | 446 | 10 | 3 | int:STAT3 | |
| Interaction | SMAD3 interactions | 1.16e-03 | 447 | 10 | 3 | int:SMAD3 | |
| Interaction | SSBP2 interactions | 1.18e-03 | 105 | 10 | 2 | int:SSBP2 | |
| Interaction | ZNF444 interactions | 1.20e-03 | 106 | 10 | 2 | int:ZNF444 | |
| Interaction | POLR3C interactions | 1.29e-03 | 110 | 10 | 2 | int:POLR3C | |
| Interaction | PAX8 interactions | 1.31e-03 | 111 | 10 | 2 | int:PAX8 | |
| Interaction | USP24 interactions | 1.34e-03 | 112 | 10 | 2 | int:USP24 | |
| Interaction | TBR1 interactions | 1.36e-03 | 113 | 10 | 2 | int:TBR1 | |
| Interaction | LDB1 interactions | 1.41e-03 | 115 | 10 | 2 | int:LDB1 | |
| Interaction | JUNB interactions | 1.48e-03 | 118 | 10 | 2 | int:JUNB | |
| Interaction | SSBP3 interactions | 1.51e-03 | 119 | 10 | 2 | int:SSBP3 | |
| Interaction | DDIT3 interactions | 1.53e-03 | 120 | 10 | 2 | int:DDIT3 | |
| Interaction | ETS1 interactions | 1.56e-03 | 121 | 10 | 2 | int:ETS1 | |
| Interaction | RBL1 interactions | 1.56e-03 | 121 | 10 | 2 | int:RBL1 | |
| Interaction | FOXO3 interactions | 1.64e-03 | 124 | 10 | 2 | int:FOXO3 | |
| Interaction | PAX7 interactions | 1.64e-03 | 124 | 10 | 2 | int:PAX7 | |
| Interaction | SRCAP interactions | 1.72e-03 | 127 | 10 | 2 | int:SRCAP | |
| Interaction | SMAD7 interactions | 1.72e-03 | 127 | 10 | 2 | int:SMAD7 | |
| Interaction | RABL6 interactions | 1.80e-03 | 130 | 10 | 2 | int:RABL6 | |
| Interaction | PAX9 interactions | 1.80e-03 | 130 | 10 | 2 | int:PAX9 | |
| Interaction | STAT5A interactions | 1.82e-03 | 131 | 10 | 2 | int:STAT5A | |
| Interaction | AHR interactions | 1.85e-03 | 132 | 10 | 2 | int:AHR | |
| Interaction | SOX15 interactions | 2.11e-03 | 141 | 10 | 2 | int:SOX15 | |
| Interaction | NCOA2 interactions | 2.11e-03 | 141 | 10 | 2 | int:NCOA2 | |
| Coexpression | GSE40666_UNTREATED_VS_IFNA_STIM_STAT1_KO_CD8_TCELL_90MIN_DN | 4.90e-05 | 198 | 10 | 3 | M9234 | |
| Coexpression | HUTTMANN_B_CLL_POOR_SURVIVAL_DN | 2.22e-04 | 59 | 10 | 2 | M12653 | |
| Coexpression | PUJANA_BREAST_CANCER_LIT_INT_NETWORK | 6.48e-04 | 101 | 10 | 2 | M15356 | |
| Coexpression | NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_UP | 1.05e-03 | 562 | 10 | 3 | M41008 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_5_6WK_DN | 1.12e-03 | 133 | 10 | 2 | M8880 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_5_6WK_DN | 1.19e-03 | 137 | 10 | 2 | MM990 | |
| Coexpression | KRAS.KIDNEY_UP.V1_UP | 1.24e-03 | 140 | 10 | 2 | M2892 | |
| Coexpression | KRAS.BREAST_UP.V1_DN | 1.29e-03 | 143 | 10 | 2 | M2887 | |
| Coexpression | LAKE_ADULT_KIDNEY_C27_VASCULAR_SMOOTH_MUSCLE_CELLS_AND_PERICYTES | 1.52e-03 | 155 | 10 | 2 | M39246 | |
| Coexpression | GSE25677_MPL_VS_MPL_AND_R848_STIM_BCELL_UP | 1.61e-03 | 160 | 10 | 2 | M8183 | |
| Coexpression | GSE6269_HEALTHY_VS_STAPH_AUREUS_INF_PBMC_UP | 1.84e-03 | 171 | 10 | 2 | M5655 | |
| Coexpression | GSE32901_TH1_VS_TH17_ENRICHED_CD4_TCELL_UP | 1.90e-03 | 174 | 10 | 2 | M8925 | |
| Coexpression | LAKE_ADULT_KIDNEY_C26_MESANGIAL_CELLS | 1.97e-03 | 177 | 10 | 2 | M39245 | |
| Coexpression | GSE10856_CTRL_VS_TNFRSF6B_IN_MACROPHAGE_UP | 2.19e-03 | 187 | 10 | 2 | M3100 | |
| Coexpression | GSE13738_RESTING_VS_BYSTANDER_ACTIVATED_CD4_TCELL_UP | 2.36e-03 | 194 | 10 | 2 | M3321 | |
| Coexpression | GSE2706_2H_VS_8H_R848_STIM_DC_UP | 2.36e-03 | 194 | 10 | 2 | M4729 | |
| Coexpression | GSE22886_CD4_TCELL_VS_BCELL_NAIVE_DN | 2.41e-03 | 196 | 10 | 2 | M4431 | |
| Coexpression | GSE16755_CTRL_VS_IFNA_TREATED_MAC_UP | 2.41e-03 | 196 | 10 | 2 | M3668 | |
| Coexpression | GSE19374_UNINF_VS_LISTERIA_INFECTED_MACROPHAGE_UP | 2.43e-03 | 197 | 10 | 2 | M7264 | |
| Coexpression | GSE26290_CTRL_VS_AKT_INHIBITOR_TREATED_ANTI_CD3_AND_IL2_STIM_CD8_TCELL_DN | 2.43e-03 | 197 | 10 | 2 | M8133 | |
| Coexpression | GSE2585_AIRE_KO_VS_WT_CD80_LOW_MTEC_UP | 2.43e-03 | 197 | 10 | 2 | M6278 | |
| Coexpression | GSE30971_WBP7_HET_VS_KO_MACROPHAGE_4H_LPS_STIM_DN | 2.43e-03 | 197 | 10 | 2 | M8726 | |
| Coexpression | GSE22886_CD8_TCELL_VS_BCELL_NAIVE_DN | 2.46e-03 | 198 | 10 | 2 | M4429 | |
| Coexpression | GSE22886_TCELL_VS_BCELL_NAIVE_DN | 2.46e-03 | 198 | 10 | 2 | M4426 | |
| Coexpression | GSE36888_STAT5_AB_KNOCKIN_VS_WT_TCELL_IL2_TREATED_2H_UP | 2.46e-03 | 198 | 10 | 2 | M8730 | |
| Coexpression | GSE45881_CXCR6HI_VS_CXCR1LO_COLONIC_LAMINA_PROPRIA_DN | 2.48e-03 | 199 | 10 | 2 | M9890 | |
| Coexpression | GSE18281_SUBCAPSULAR_CORTICAL_REGION_VS_WHOLE_MEDULLA_THYMUS_UP | 2.48e-03 | 199 | 10 | 2 | M7254 | |
| Coexpression | GSE18281_PERIMEDULLARY_CORTICAL_REGION_VS_WHOLE_MEDULLA_THYMUS_UP | 2.48e-03 | 199 | 10 | 2 | M7259 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_6_7WK_UP | 2.48e-03 | 199 | 10 | 2 | MM991 | |
| Coexpression | GSE3039_NKT_CELL_VS_B1_BCELL_UP | 2.48e-03 | 199 | 10 | 2 | M6432 | |
| Coexpression | GSE7764_IL15_NK_CELL_24H_VS_SPLENOCYTE_DN | 2.48e-03 | 199 | 10 | 2 | M5726 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_6_7WK_UP | 2.48e-03 | 199 | 10 | 2 | M2155 | |
| Coexpression | GSE36888_UNTREATED_VS_IL2_TREATED_TCELL_17H_UP | 2.48e-03 | 199 | 10 | 2 | M8734 | |
| Coexpression | GSE360_L_MAJOR_VS_M_TUBERCULOSIS_DC_UP | 2.48e-03 | 199 | 10 | 2 | M5213 | |
| Coexpression | GSE22886_NAIVE_CD4_TCELL_VS_12H_ACT_TH2_UP | 2.48e-03 | 199 | 10 | 2 | M4526 | |
| Coexpression | GSE17721_POLYIC_VS_CPG_6H_BMDC_UP | 2.50e-03 | 200 | 10 | 2 | M3943 | |
| Coexpression | GSE18893_CTRL_VS_TNF_TREATED_TREG_2H_UP | 2.50e-03 | 200 | 10 | 2 | M7294 | |
| Coexpression | GSE17721_PAM3CSK4_VS_GADIQUIMOD_6H_BMDC_DN | 2.50e-03 | 200 | 10 | 2 | M3971 | |
| Coexpression | GSE22313_HEALTHY_VS_SLE_MOUSE_CD4_TCELL_DN | 2.50e-03 | 200 | 10 | 2 | M8584 | |
| Coexpression | GSE32423_MEMORY_VS_NAIVE_CD8_TCELL_DN | 2.50e-03 | 200 | 10 | 2 | M5073 | |
| Coexpression | GSE19941_UNSTIM_VS_LPS_STIM_IL10_KO_MACROPHAGE_DN | 2.50e-03 | 200 | 10 | 2 | M8106 | |
| Coexpression | GSE23308_CTRL_VS_CORTICOSTERONE_TREATED_MACROPHAGE_MINERALCORTICOID_REC_KO_DN | 2.50e-03 | 200 | 10 | 2 | M7744 | |
| Coexpression | GSE8921_UNSTIM_0H_VS_TLR1_2_STIM_MONOCYTE_12H_DN | 2.50e-03 | 200 | 10 | 2 | M6408 | |
| Coexpression | GSE7852_LN_VS_FAT_TCONV_UP | 2.50e-03 | 200 | 10 | 2 | M5747 | |
| Coexpression | GSE5589_LPS_AND_IL10_VS_LPS_AND_IL6_STIM_MACROPHAGE_45MIN_UP | 2.50e-03 | 200 | 10 | 2 | M6613 | |
| Coexpression | GSE23984_CTRL_VS_HYPOCALEMIC_VITAMIND_ANALOG_TCELL_DN | 2.50e-03 | 200 | 10 | 2 | M8052 | |
| Coexpression | GSE1432_6H_VS_24H_IFNG_MICROGLIA_UP | 2.50e-03 | 200 | 10 | 2 | M3415 | |
| Coexpression | GSE10240_IL22_VS_IL22_AND_IL17_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_DN | 2.50e-03 | 200 | 10 | 2 | M309 | |
| Coexpression | STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP | 2.65e-03 | 206 | 10 | 2 | M2817 | |
| Coexpression | STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP | 2.70e-03 | 208 | 10 | 2 | MM581 | |
| Coexpression | LAKE_ADULT_KIDNEY_C2_PODOCYTES | 2.81e-03 | 212 | 10 | 2 | M39221 | |
| Coexpression | TABULA_MURIS_SENIS_PANCREAS_PANCREATIC_BETA_CELL_AGEING | 2.81e-03 | 212 | 10 | 2 | MM3816 | |
| ToppCell | droplet-Marrow-nan-3m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.91e-06 | 184 | 10 | 3 | 1154a5ad7b8512272b7476f949ddac350910bfb7 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_memory-B_activate-7|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.20e-04 | 139 | 10 | 2 | 693ca81f5831b63fe6148ac755631e09f67d0ebf | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-14|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.88e-04 | 150 | 10 | 2 | 4bdcdce40f54580c7a4e1416b468e657ba8874fc | |
| ToppCell | COVID-19_Mild-PLT_0|World / Disease Group and Platelet Clusters | 5.01e-04 | 152 | 10 | 2 | d49f7c0681500fc4d93818d47e8e8afb726c23d9 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-5|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.14e-04 | 154 | 10 | 2 | 020697ae8463b18f9b4270c404f52ce4c0e90135 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_5|390C / Donor, Lineage, Cell class and subclass (all cells) | 5.21e-04 | 155 | 10 | 2 | afdd0aba0f3788c2fb916ffb453c5dd7cde2304c | |
| ToppCell | COVID-CD4-CD4_Treg|COVID / Condition, Cell_class and T cell subcluster | 5.48e-04 | 159 | 10 | 2 | 037cd97c41eb2f91fd3f69bbb3ffdfd6c0158410 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive-B_naive-11|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.55e-04 | 160 | 10 | 2 | 8396afbc7d919ba190863d50aa0ef8b9942a9866 | |
| ToppCell | normal-na-Lymphocytic_B-B_cell-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.69e-04 | 162 | 10 | 2 | ae292318d339305932457bb0e91430594f7a3dfa | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal--glomerular_mesenchymal_cell-Renin-positive_Juxtaglomerular_Granular_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.83e-04 | 164 | 10 | 2 | 43630a448f4369fa9e4e3eccdf3b9f29cec16c39 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal--glomerular_mesenchymal_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.83e-04 | 164 | 10 | 2 | 46208f18325976c89f572f6627aea0582142b92d | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.83e-04 | 164 | 10 | 2 | 108fbecb56d69a675d6ce6e826a873ae528f2fd7 | |
| ToppCell | 343B-Lymphocytic-Plasma_cell|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 5.83e-04 | 164 | 10 | 2 | cf62d34ce9dd220fe61748466c84fd70d9ba697c | |
| ToppCell | 343B-Lymphocytic-Plasma_cell-|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 5.83e-04 | 164 | 10 | 2 | e00549bc8b3a5566f39031f39d7e698b0b107a7f | |
| ToppCell | normal-na-Lymphocytic_B-B_atypical-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.97e-04 | 166 | 10 | 2 | 30a180b67572c3f4fb3a291f271f855e1b20005e | |
| ToppCell | ICU-NoSEP-Lymphocyte-T_NK-NK_CD56bright|ICU-NoSEP / Disease, Lineage and Cell Type | 6.04e-04 | 167 | 10 | 2 | f4f188a8efca8cdd0ecfb857fe4538c10847eadd | |
| ToppCell | BAL-Severe-Myeloid-cDC-cDC-cDC_4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 6.12e-04 | 168 | 10 | 2 | d60f7cd8269f373827f49c7785002cb38e4570a9 | |
| ToppCell | BAL-Severe-Myeloid-cDC-cDC-cDC_4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 6.19e-04 | 169 | 10 | 2 | ccd98f9005aa0a88bd49f153be4e7200cc3dd0ac | |
| ToppCell | 3'_v3-bone_marrow-Lymphocytic_B-ABC_aged-B_naive|bone_marrow / Manually curated celltypes from each tissue | 6.33e-04 | 171 | 10 | 2 | fcc31a9a69f96de10d1324a5a4fbfe4289bf4984 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.41e-04 | 172 | 10 | 2 | 08a3fe536b1b064c5ee7779bc2b1115a5963a26b | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.41e-04 | 172 | 10 | 2 | 553701349444eb366df3c11f54bb093434f153c6 | |
| ToppCell | facs-Lung-Endomucin_-18m-Myeloid-Nonclassical_Monocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.48e-04 | 173 | 10 | 2 | a4ed191cfdf6588b7f3672995bf0a4fe9e4b8df6 | |
| ToppCell | severe-B_memory|severe / disease stage, cell group and cell class | 6.48e-04 | 173 | 10 | 2 | 3a987ac53a0136cc4c70ce8b901a15fc00c795e1 | |
| ToppCell | facs-Lung-Endomucin_-18m-Myeloid-non-classical_monocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.48e-04 | 173 | 10 | 2 | c31076c725f4cd912c56903592a2d9356ae59f54 | |
| ToppCell | droplet-Thymus-nan-3m-Lymphocytic-Double_negative_thymocyte,_DN3_(Cd8-,_Cd4-),_some_express_pre_TCR_alpha|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.56e-04 | 174 | 10 | 2 | 0fccd90ef72ec2e5eb369fe6d6d126c60886485a | |
| ToppCell | droplet-Liver-LIVER_HEPATOCYTES-30m-Lymphocytic-B_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.63e-04 | 175 | 10 | 2 | 59249c9e83952d7277010e7be3c779e26399eb5d | |
| ToppCell | droplet-Liver-LIVER_HEPATOCYTES-30m-Lymphocytic-B_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.63e-04 | 175 | 10 | 2 | b35cc1357495f2a03a6500f807c6e6f8c877734d | |
| ToppCell | severe-B_memory|World / disease stage, cell group and cell class | 6.71e-04 | 176 | 10 | 2 | 4e5c6b1aa5ffd13593a6bcd1e1253c1737c5c2b4 | |
| ToppCell | 3'-Parenchyma_lung-Endothelial-Blood_vessel_EC-pulmonary_artery_endothelial_cell-EC_arterial-EC_arterial_L.2.4.1.3|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.78e-04 | 177 | 10 | 2 | 16197068260fc062bf8b730a51a199887ea580b9 | |
| ToppCell | Control-Lymphocyte-B-B_naive|Control / Disease, Lineage and Cell Type | 6.94e-04 | 179 | 10 | 2 | 35994281904bfe38766e715ab608211a5ca865a9 | |
| ToppCell | 5'-Adult-LymphNode-Epithelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.01e-04 | 180 | 10 | 2 | cc974ac352ef2adc953fb5f325880e5857595889 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_naive-B_naive-2|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 7.09e-04 | 181 | 10 | 2 | 75035a3211e524bb659b82e6979f7d3a3121ae70 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 7.09e-04 | 181 | 10 | 2 | 0c52dd82e6b3dce3d6bb5c13501bf8383f7121e4 | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.17e-04 | 182 | 10 | 2 | f8c73baaaca145e2efc48f10f636feb79c8fc779 | |
| ToppCell | 5'-Adult-LymphNode-Epithelial-epithelial_progenitor_cell-TA|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.17e-04 | 182 | 10 | 2 | 49e4b362f88d235ed12aabcabb54787c16e32cb7 | |
| ToppCell | 5'-Adult-LymphNode-Epithelial-epithelial_progenitor_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.17e-04 | 182 | 10 | 2 | cf0a6f99b825eb75f95f376c16a504e2669820ac | |
| ToppCell | (4)_B_cells-(4)_B_mantle|(4)_B_cells / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 7.25e-04 | 183 | 10 | 2 | 21b7fb6482eb1d5d31a4029e47e0992e8ddc8e2c | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.41e-04 | 185 | 10 | 2 | 7adfa929930cfa795cbfbd9f1a0b439e08aa765d | |
| ToppCell | Mild-NK|World / Disease group and Cell class | 7.41e-04 | 185 | 10 | 2 | 0565b7c464e1a09e596f5a0b363d2dc9b55c3c50 | |
| ToppCell | pdx|World / Sample and Cell Type and Tumor Cluster (all cells) | 7.48e-04 | 186 | 10 | 2 | de8e538c8767d41b8a52f5e58ba1affd4e7244c4 | |
| ToppCell | pdx-Tumor_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 7.48e-04 | 186 | 10 | 2 | 0b88a87158a9ca8de3bf40a4ff1687150707a5f0 | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 7.48e-04 | 186 | 10 | 2 | 03db813598b67b1e08f759758a1c2023396921fa | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 7.56e-04 | 187 | 10 | 2 | d01926be1c8846a25fb6706e26b56b808b69f8f0 | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 7.65e-04 | 188 | 10 | 2 | 9858940c616e43441644c5a3bea8d832ee4daf79 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive-B_naive-5|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 7.73e-04 | 189 | 10 | 2 | b4237437452f86e745b91285980c48a02a95f4c6 | |
| ToppCell | Healthy-B_naive|World / disease group, cell group and cell class | 7.73e-04 | 189 | 10 | 2 | 1e533a43f739ff295740cf2b25479756dfb8e595 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 7.81e-04 | 190 | 10 | 2 | 112706d64ee73b55dcf76f33ca064ab1fc6ce87f | |
| ToppCell | 3'_v3-bone_marrow-Lymphocytic_B-Naive_B_cells|bone_marrow / Manually curated celltypes from each tissue | 7.81e-04 | 190 | 10 | 2 | 3d45d5011305f13634013d9eeb98f235517dd54e | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B-B_lineage-pro_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 7.81e-04 | 190 | 10 | 2 | f623f0bdece6002b68ac2207e99408b24a2b1194 | |
| ToppCell | Control-Myeloid-cDC2|Control / Disease state, Lineage and Cell class | 7.81e-04 | 190 | 10 | 2 | 4e481e42353d47af7991744000403af2873f6a41 | |
| ToppCell | Control-Myeloid-cDC2|World / Disease state, Lineage and Cell class | 7.89e-04 | 191 | 10 | 2 | 11dfd8f38beb294f42710cfbd355cb089e1023c0 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_activate-7|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 7.89e-04 | 191 | 10 | 2 | 2feab42ac6d29fa4eac78f3f78a5f8aa0a559523 | |
| ToppCell | LV-08._Macrophage|World / Chamber and Cluster_Paper | 7.89e-04 | 191 | 10 | 2 | e7a0bc46ba9ba772636a583f3387748418e18832 | |
| ToppCell | COPD-Myeloid-cDC2|COPD / Disease state, Lineage and Cell class | 7.89e-04 | 191 | 10 | 2 | 2af6e4a6bd1f2193ece2131c3b7d976dd23a6966 | |
| ToppCell | IPF-Myeloid-cDC2|World / Disease state, Lineage and Cell class | 7.89e-04 | 191 | 10 | 2 | 9fda87fb6bc5b8b6c0214ec909ebbc9f3f65319b | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B-B_lineage-pro_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 7.89e-04 | 191 | 10 | 2 | 054fa0493b00149313c243d39cf39a264044f074 | |
| ToppCell | COPD-Myeloid-cDC2|World / Disease state, Lineage and Cell class | 7.89e-04 | 191 | 10 | 2 | 4e4887175200a57e1b041f2f131e3df774df3509 | |
| ToppCell | 3'_v3-bone_marrow-Lymphocytic_B|bone_marrow / Manually curated celltypes from each tissue | 7.97e-04 | 192 | 10 | 2 | 8a284b6e499f5a3c116d5551430f00ecad4a3681 | |
| ToppCell | IPF-Myeloid-cDC2|IPF / Disease state, Lineage and Cell class | 7.97e-04 | 192 | 10 | 2 | fe1de692fec48cba4a9bbc6eaa257260e8b4e800 | |
| ToppCell | (100)_CD19+_Naive_B_cell|World / immune cells in Peripheral Blood (logTPM normalization) | 7.97e-04 | 192 | 10 | 2 | ae7e6ed7b6cc1dd45bc0547783515beecad7792a | |
| ToppCell | Healthy-B_naive|Healthy / disease group, cell group and cell class | 7.97e-04 | 192 | 10 | 2 | 5fddf679dcc9c0077d6bfe04c1e602863fb959eb | |
| ToppCell | COPD-Myeloid-cDC2|Myeloid / Disease state, Lineage and Cell class | 7.97e-04 | 192 | 10 | 2 | 984cdc2f1d93e164bc946d63f58dacb629f82eb7 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive-B_naive-13|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 7.97e-04 | 192 | 10 | 2 | e5ab932b4c2fed538161281ae07dfcdd82706fdd | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_MHC-E|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.97e-04 | 192 | 10 | 2 | fcdb2e924800457d21e4aaeeedd81dbf80216eed | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_B-Naive_B_cells|lymph-node_spleen / Manually curated celltypes from each tissue | 8.05e-04 | 193 | 10 | 2 | eb497d62a45ad77b2578b03a84cb3edc83207be5 | |
| ToppCell | Children_(3_yrs)-Immune-monocyte-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.05e-04 | 193 | 10 | 2 | 58e1930a1d80ad3729ab9604ac8ebf7308232a3d | |
| ToppCell | PBMC-Severe-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_1|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 8.05e-04 | 193 | 10 | 2 | 4fb020f11fd7aff06952bfeaabc79b2c7b8873f6 | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m-Myeloid-microglial_cell|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.05e-04 | 193 | 10 | 2 | 9c16032bc03df8760ae199e8f19fdafa4c3f1827 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-6|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 8.14e-04 | 194 | 10 | 2 | 2b5eee7c3e52b63cce94205d18133c7704329c02 | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.14e-04 | 194 | 10 | 2 | 66c056232ac216780acf4cc8ea325bd8ed1909c9 | |
| ToppCell | facs-Thymus-nan-3m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.14e-04 | 194 | 10 | 2 | f1661f9f2439fca5c1012c693b0744c4e3b90a9b | |
| ToppCell | PBMC-Severe-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_1|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 8.14e-04 | 194 | 10 | 2 | 885355ebe98e974f841cc59dce3b5228c642c5d0 | |
| ToppCell | IPF-Myeloid-cDC2|Myeloid / Disease state, Lineage and Cell class | 8.14e-04 | 194 | 10 | 2 | accf4b7b09e2048f2e47a52201e0158684dda8fe | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B-B_lineage-pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 8.14e-04 | 194 | 10 | 2 | f64da5f62e29253d60b9546edf734ba5c17daae1 | |
| ToppCell | facs-Thymus-nan|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.14e-04 | 194 | 10 | 2 | cda1b197efb199330ea7ab25a7cee22cae22589d | |
| ToppCell | Mild-NK|Mild / Disease group and Cell class | 8.22e-04 | 195 | 10 | 2 | be88a7507cd6a0a9dfe424312d9365039eef7b74 | |
| ToppCell | Children_(3_yrs)-Immune-monocyte-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.22e-04 | 195 | 10 | 2 | 81a28289eda1a8a1a31b7357106f64ac5000e172 | |
| ToppCell | facs-Brain_Myeloid-Hippocampus|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.22e-04 | 195 | 10 | 2 | a1478021a3ed0e779716393124ca2a7770c433b7 | |
| ToppCell | Children_(3_yrs)-Immune-monocyte|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.30e-04 | 196 | 10 | 2 | cacd69be72e6167814f7adea7c5fa114f3103bbb | |
| ToppCell | Sepsis-Bac-SEP-Lymphocyte-B-B_intermediate|Bac-SEP / Disease, condition lineage and cell class | 8.30e-04 | 196 | 10 | 2 | 1611920211beb1a3691e3853e0314792a74279a0 | |
| ToppCell | control-B_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.39e-04 | 197 | 10 | 2 | 559650fb53f18ecae4cfaa8221e978ae3fb63e06 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Monocytic|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 8.39e-04 | 197 | 10 | 2 | 1eb9ff8467118b943b5d443cb996168e1e1206b5 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 8.39e-04 | 197 | 10 | 2 | 8af4a1e35ce9fb4ea3d26ab619599efb7eac43a5 | |
| ToppCell | Monocytes-cDCs|World / Immune cells in Kidney/Urine in Lupus Nephritis | 8.39e-04 | 197 | 10 | 2 | 3388c104af4c6a05988e102627e0c5e34d9dcc45 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Layer_VI_Pan-area-33|World / Primary Cells by Cluster | 8.39e-04 | 197 | 10 | 2 | d20f29088e9afd8a960d6f680075c380e550f8a7 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Layer_VI_Pan-area|World / Primary Cells by Cluster | 8.39e-04 | 197 | 10 | 2 | 79b9e7f2e8e33b3c547f716be5667156c48b0dfc | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 8.47e-04 | 198 | 10 | 2 | 8aa4149d2c1cec73cfd654db093252ec8ec5ef68 | |
| ToppCell | control-B_naive|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.47e-04 | 198 | 10 | 2 | c012b8fbfa8bbc5014217f47acf9177470d8a65a | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Layer_IV-2|World / Primary Cells by Cluster | 8.56e-04 | 199 | 10 | 2 | f09b40245d3d826275bbe5f508dedccc75a911bd | |
| ToppCell | mild-B_memory|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.56e-04 | 199 | 10 | 2 | e6ac9a0959b0de2c6a99298feb7715aa80ade1dd | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 8.56e-04 | 199 | 10 | 2 | 5478b78349b5d8d57f30bb650dcbd5fdb84283d6 | |
| ToppCell | Neuron-Postmitotic|World / Primary Cells by Cluster | 8.56e-04 | 199 | 10 | 2 | 1973527f8a7d4c6490d75c0d0ea153688166a08b | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 8.56e-04 | 199 | 10 | 2 | 8e7f9312dec1e3a92b6a0ccc7baa2d46e89c11f3 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Layer_IV|World / Primary Cells by Cluster | 8.56e-04 | 199 | 10 | 2 | e45448ec4db8875c8aaa9aad109a10e2905a4226 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Hematopoietic-B_cells-Cycling_plasma_cell|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 8.56e-04 | 199 | 10 | 2 | c9d15c84b9f8c87b4ea0008be7d5efc5f45efd1a | |
| ToppCell | erythropoietic-Basophilic_Erythroblast|erythropoietic / Lineage and Cell class | 8.56e-04 | 199 | 10 | 2 | 39c4adef3e02f948414f866aa22ac76f44b7b7db | |
| ToppCell | mild-B_memory|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.56e-04 | 199 | 10 | 2 | 025bb65629d9e20c374e8f1ba08c36d1bb569190 | |
| ToppCell | Neuron|World / Primary Cells by Cluster | 8.56e-04 | 199 | 10 | 2 | 1f8104fd92f04690b41d9d07ac08dc59d76bb97d | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 8.56e-04 | 199 | 10 | 2 | 8daf945fc93169b0a4fa3ef9f4a87eedd52e314a | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_|World / Primary Cells by Cluster | 8.56e-04 | 199 | 10 | 2 | 058373b4ac3cec2108cb24265628ff0a50646e33 | |
| Drug | 17-AAG; Down 200; 1uM; SKMEL5; HG-U133A | 7.10e-05 | 195 | 10 | 3 | 505_DN | |
| Drug | tricetin | 1.09e-04 | 36 | 10 | 2 | CID005281701 | |
| Drug | AC1O59H4 | 2.55e-04 | 55 | 10 | 2 | CID006480473 | |
| Drug | GGTI-298 | 3.34e-04 | 63 | 10 | 2 | CID009811606 | |
| Drug | IPPD | 3.67e-04 | 66 | 10 | 2 | CID000007573 | |
| Drug | tetrabromobisphenol A | 4.05e-04 | 891 | 10 | 4 | ctd:C020806 | |
| Drug | Dihydrotestosterone | 4.33e-04 | 360 | 10 | 3 | ctd:D013196 | |
| Drug | R A J | 4.61e-04 | 74 | 10 | 2 | CID011497471 | |
| Drug | ribose-5-P | 1.05e-03 | 112 | 10 | 2 | CID000439167 | |
| Drug | M50054 | 1.15e-03 | 117 | 10 | 2 | CID002748618 | |
| Drug | AC1OCADI | 1.41e-03 | 130 | 10 | 2 | CID006914639 | |
| Drug | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole | 1.57e-03 | 137 | 10 | 2 | ctd:C090942 | |
| Drug | 5-aza-2'-deoxycytidine | 2.27e-03 | 638 | 10 | 3 | CID000016886 | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 2.37e-03 | 169 | 10 | 2 | 5231_DN | |
| Drug | SAHA; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 2.43e-03 | 171 | 10 | 2 | 1000_DN | |
| Drug | irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A | 2.43e-03 | 171 | 10 | 2 | 7535_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 2.45e-03 | 172 | 10 | 2 | 1072_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 2.54e-03 | 175 | 10 | 2 | 1014_DN | |
| Drug | Nocodazole [31430-18-9]; Up 200; 13.2uM; HL60; HG-U133A | 2.57e-03 | 176 | 10 | 2 | 1393_UP | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.60e-03 | 177 | 10 | 2 | 3227_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A | 2.68e-03 | 180 | 10 | 2 | 6886_DN | |
| Drug | Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A | 2.68e-03 | 180 | 10 | 2 | 4541_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 2.71e-03 | 181 | 10 | 2 | 6951_DN | |
| Drug | Ritodrine hydrochloride [23239-51-2]; Up 200; 12.4uM; HL60; HT_HG-U133A | 2.74e-03 | 182 | 10 | 2 | 1280_UP | |
| Drug | STOCK1N-35215; Up 200; 10uM; PC3; HT_HG-U133A | 2.74e-03 | 182 | 10 | 2 | 6427_UP | |
| Drug | 17-AAG; Down 200; 1uM; PC3; HT_HG-U133A | 2.80e-03 | 184 | 10 | 2 | 4430_DN | |
| Drug | Mometasone furoate [83919-23-7]; Down 200; 7.6uM; PC3; HT_HG-U133A | 2.92e-03 | 188 | 10 | 2 | 5116_DN | |
| Drug | Nifuroxazide [965-52-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A | 2.92e-03 | 188 | 10 | 2 | 4835_DN | |
| Drug | 2-propylpentanoic acid; Up 200; 1000uM; MCF7; HT_HG-U133A_EA | 2.95e-03 | 189 | 10 | 2 | 989_UP | |
| Drug | radicicol; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA | 2.98e-03 | 190 | 10 | 2 | 836_DN | |
| Drug | Azacytidine-5 [320-67-2]; Down 200; 16.4uM; MCF7; HT_HG-U133A | 2.98e-03 | 190 | 10 | 2 | 4128_DN | |
| Drug | C75; Down 200; 10uM; PC3; HT_HG-U133A | 3.01e-03 | 191 | 10 | 2 | 6399_DN | |
| Drug | 5707885; Down 200; 50uM; PC3; HT_HG-U133A | 3.01e-03 | 191 | 10 | 2 | 6390_DN | |
| Drug | rottlerin; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 3.01e-03 | 191 | 10 | 2 | 941_DN | |
| Drug | Isotretinoin [4759-48-2]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 3.01e-03 | 191 | 10 | 2 | 7438_DN | |
| Drug | Niclosamide | 3.01e-03 | 191 | 10 | 2 | ctd:D009534 | |
| Drug | Niclosamide [50-65-7]; Down 200; 12.2uM; PC3; HT_HG-U133A | 3.04e-03 | 192 | 10 | 2 | 4018_DN | |
| Drug | Azacyclonol [115-46-8]; Down 200; 15uM; PC3; HG-U133A | 3.04e-03 | 192 | 10 | 2 | 1937_DN | |
| Drug | Prochlorperazine dimaleate [84-02-6]; Down 200; 6.6uM; HL60; HT_HG-U133A | 3.04e-03 | 192 | 10 | 2 | 1286_DN | |
| Drug | Fusaric acid [536-69-6]; Down 200; 22.4uM; MCF7; HT_HG-U133A | 3.04e-03 | 192 | 10 | 2 | 3245_DN | |
| Drug | Triprolidine hydrochloride [550-70-9]; Up 200; 12.8uM; PC3; HT_HG-U133A | 3.04e-03 | 192 | 10 | 2 | 7248_UP | |
| Drug | 2-propylpentanoic acid; Up 200; 1000uM; SKMEL5; HG-U133A | 3.04e-03 | 192 | 10 | 2 | 629_UP | |
| Drug | Triprolidine hydrochloride [550-70-9]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 3.08e-03 | 193 | 10 | 2 | 7008_DN | |
| Drug | Pentolinium bitartrate [52-62-0]; Down 200; 7.4uM; PC3; HT_HG-U133A | 3.08e-03 | 193 | 10 | 2 | 7375_DN | |
| Drug | Hycanthone [3105-97-3]; Down 200; 11.2uM; PC3; HT_HG-U133A | 3.08e-03 | 193 | 10 | 2 | 4630_DN | |
| Drug | Antimycin A [1397-94-0]; Down 200; 7.2uM; PC3; HT_HG-U133A | 3.08e-03 | 193 | 10 | 2 | 2098_DN | |
| Drug | troglitazone; Up 200; 10uM; MCF7; HT_HG-U133A | 3.08e-03 | 193 | 10 | 2 | 1657_UP | |
| Drug | carmustine; Down 200; 100uM; PC3; HT_HG-U133A | 3.11e-03 | 194 | 10 | 2 | 6883_DN | |
| Drug | paclitaxel; Down 200; 0.1uM; MCF7; HG-U133A | 3.11e-03 | 194 | 10 | 2 | 640_DN | |
| Drug | Betazole hydrochloride; Up 200; 27uM; PC3; HT_HG-U133A | 3.11e-03 | 194 | 10 | 2 | 1812_UP | |
| Drug | Methylprednisolone, 6-alpha [83-43-2]; Down 200; 10.6uM; PC3; HT_HG-U133A | 3.11e-03 | 194 | 10 | 2 | 7137_DN | |
| Drug | Griseofulvin [126-07-8]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 3.11e-03 | 194 | 10 | 2 | 2293_DN | |
| Drug | H-89, Dihydrochloride; Up 200; 0.5uM; MCF7; HT_HG-U133A | 3.11e-03 | 194 | 10 | 2 | 6878_UP | |
| Drug | Methotrimeprazine maleat salt [7104-38-3]; Up 200; 9uM; MCF7; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 4723_UP | |
| Drug | Canrenoic acid potassium salt [2181-04-6]; Up 200; 10uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 7135_UP | |
| Drug | Sulfadimethoxine [122-11-2]; Down 200; 12.8uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 7400_DN | |
| Drug | Protriptyline hydrochloride [1225-55-4]; Down 200; 13.4uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 6338_DN | |
| Drug | Amoxapine [14028-44-5]; Down 200; 12.8uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 6650_DN | |
| Drug | Perphenazine [58-39-9]; Down 200; 10uM; PC3; HG-U133A | 3.14e-03 | 195 | 10 | 2 | 1956_DN | |
| Drug | Tiaprofenic acid [33005-95-7]; Down 200; 15.4uM; MCF7; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 2852_DN | |
| Drug | Metolazone [17560-51-9]; Down 200; 11uM; PC3; HG-U133A | 3.14e-03 | 195 | 10 | 2 | 1932_DN | |
| Drug | Cefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 7385_DN | |
| Drug | Tolazamide [1156-19-0]; Up 200; 12.8uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 4003_UP | |
| Drug | Propoxycaine hydrochloride [550-83-4]; Down 200; 12uM; MCF7; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 3583_DN | |
| Drug | PHA-00851261E [724719-49-7]; Down 200; 1uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 4333_DN | |
| Drug | Picotamide monohydrate [80530-63-8]; Up 200; 10.2uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 7140_UP | |
| Drug | Oxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; HL60; HG-U133A | 3.14e-03 | 195 | 10 | 2 | 1431_DN | |
| Drug | Sulindac [38194-50-2]; Down 200; 11.2uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 5103_DN | |
| Drug | Ursolic acid [77-52-1]; Down 200; 8.8uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 5825_DN | |
| Drug | Xylazine [7361-61-7]; Up 200; 18.2uM; HL60; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 2132_UP | |
| Drug | Apramycin [37321-09-8]; Down 200; 7.4uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 6614_DN | |
| Drug | Beclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; PC3; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 4580_DN | |
| Drug | (1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 6053_UP | |
| Drug | Pregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 4802_DN | |
| Drug | Troleandomycin [2751-09-9]; Down 200; 5uM; MCF7; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 1465_DN | |
| Drug | Sisomicin sulfate [53179-09-2]; Down 200; 2.8uM; HL60; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 2493_DN | |
| Drug | Mafenide hydrochloride [138-37-4]; Down 200; 18uM; PC3; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 5079_DN | |
| Drug | Picotamide monohydrate [80530-63-8]; Up 200; 10.2uM; MCF7; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 2233_UP | |
| Drug | Naltrexone hydrochloride dihydrate [16676-29-2]; Down 200; 9.6uM; PC3; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 5765_DN | |
| Drug | (-)-Eseroline fumarate salt [104015-29-4]; Up 200; 12uM; MCF7; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 3530_UP | |
| Drug | 3-Acetamidocoumarin [779-30-6]; Down 200; 19.6uM; HL60; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 2941_DN | |
| Drug | Rapamycin; Down 200; 0.1uM; PC3; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 4445_DN | |
| Drug | staurosporine; Down 200; 0.01uM; SKMEL5; HG-U133A | 3.17e-03 | 196 | 10 | 2 | 508_DN | |
| Drug | Nalidixic acid sodium salt hydrate; Down 200; 14.6uM; PC3; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 7367_DN | |
| Drug | BAS 012416453; Up 200; 38uM; MCF7; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 6880_UP | |
| Drug | haloperidol; Up 200; 10uM; MCF7; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 6923_UP | |
| Drug | oligomycin; Down 200; 1uM; MCF7; HG-U133A | 3.17e-03 | 196 | 10 | 2 | 442_DN | |
| Disease | Adenoid Cystic Carcinoma | 4.45e-06 | 100 | 10 | 3 | C0010606 | |
| Disease | Sarcoma, Spindle Cell | 9.39e-06 | 14 | 10 | 2 | C0205945 | |
| Disease | Sarcoma, Epithelioid | 9.39e-06 | 14 | 10 | 2 | C0205944 | |
| Disease | Sarcoma | 2.16e-05 | 21 | 10 | 2 | C1261473 | |
| Disease | Small cell carcinoma of lung | 1.47e-04 | 54 | 10 | 2 | C0149925 | |
| Disease | Psychotic Disorders | 5.13e-04 | 101 | 10 | 2 | C0033975 | |
| Disease | ovarian neoplasm | 8.99e-04 | 134 | 10 | 2 | C0919267 | |
| Disease | Malignant neoplasm of ovary | 9.40e-04 | 137 | 10 | 2 | C1140680 | |
| Disease | prostate cancer (is_marker_for) | 1.22e-03 | 156 | 10 | 2 | DOID:10283 (is_marker_for) | |
| Disease | alcohol use disorder (implicated_via_orthology) | 1.89e-03 | 195 | 10 | 2 | DOID:1574 (implicated_via_orthology) | |
| Disease | Alzheimer disease, educational attainment | 3.00e-03 | 247 | 10 | 2 | EFO_0011015, MONDO_0004975 | |
| Disease | diet measurement | 4.46e-03 | 1049 | 10 | 3 | EFO_0008111 | |
| Disease | household income | 4.51e-03 | 304 | 10 | 2 | EFO_0009695 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| PPDSLMKMPLSNGQM | 1246 | Q96RT1 | |
| MKMPLSNGQMGQPLR | 1251 | Q96RT1 | |
| LRGPQPLKMGMMNNP | 236 | Q09472 | |
| PLKMGMMNNPNPYGS | 241 | Q09472 | |
| PNGPKMGLLMMILGQ | 576 | Q9HCI5 | |
| LNPAAMGRQMMPSLP | 1021 | Q96JK9 | |
| SRMAKMGQPMLPILP | 366 | Q5T1M5 | |
| MQAKSPPPMNLGMNN | 236 | Q06413 | |
| GMMGPQQNIMIPPQM | 1386 | O00512 | |
| QQNIMIPPQMRPRGM | 1391 | O00512 | |
| GKRPMPGMQQQMPTL | 206 | P51532 | |
| GMKKGLFPMNPMIPQ | 2376 | Q9C0A1 | |
| MPVPQMMNFGLPSLA | 501 | A7XYQ1 |